DOJ Expands Probe into UnitedHealth, Targeting Optum Rx and Physician Reimbursements

The United States Department of Justice (DOJ) has significantly expanded its investigation into UnitedHealth Group, one of the nation’s largest healthcare conglomerates. What began as a probe into Medicare fraud has now extended to include the company’s pharmacy benefits manager, Optum Rx, and its physician reimbursement practices. This broader investigation underscores the mounting scrutiny on UnitedHealth’s operations and raises significant questions about its business practices.

How the DOJ Investigation Has Evolved

Initially, the DOJ’s criminal probe centered around allegations of Medicare Advantage fraud, specifically whether UnitedHealth had manipulated diagnostic codes to increase federal reimbursements. However, according to a recent report by Bloomberg on August 26, the investigation now includes Optum Rx, a key subsidiary responsible for prescription drug management and reimbursements to physicians. Optum Rx is one of the top three pharmacy benefits managers in the U.S., making it a critical player in the healthcare industry.

The DOJ is scrutinizing how Optum Rx dispenses medications through its mail-order and specialty pharmacies and whether its reimbursement practices for doctors align with federal guidelines. This expanded scope has added layers of complexity to an already intricate investigation. The company has not been officially accused of wrongdoing but faces both civil and criminal inquiries, as well as antitrust scrutiny from the Federal Trade Commission (FTC).

Financial and Reputational Consequences for UnitedHealth

The ongoing investigations have had a noticeable impact on UnitedHealth’s financial performance. As reported by Fierce Healthcare, the company’s stock has experienced volatility, with shares losing approximately 40% of their value this year. Investor confidence has been shaken by a series of setbacks, including the resignation of CEO Andrew Witty in May and disappointing earnings related to its Medicare Advantage operations.

Adding to the financial strain is a separate civil fraud lawsuit concerning Medicare billing practices. The FTC is also pursuing an antitrust investigation into the relationship between UnitedHealth’s UnitedHealthcare and Optum units, focusing on potential conflicts of interest and anti-competitive behavior. These cumulative challenges have prompted UnitedHealth to form a new committee within its board of directors to oversee compliance and reputational risks, particularly in its pharmacy benefits management segment.

UnitedHealth’s Defense and Efforts to Mitigate Risks

In response to the DOJ’s expanded probe, UnitedHealth has maintained its stance of confidence in its practices. A statement issued by the company emphasized its long history of compliance and responsible conduct. As reported by Market Screener, UnitedHealth has proactively initiated third-party audits to ensure adherence to federal regulations. The company also noted that independent audits by the Centers for Medicare & Medicaid Services (CMS) have found its practices to be among the most accurate in the industry.

Despite these assurances, the DOJ has reportedly interviewed former employees as part of its investigation, raising concerns about internal practices. Some physicians have been questioned about training programs aimed at maximizing diagnoses for Medicare reimbursements, a practice that could have contributed to inflated billing. UnitedHealth has pledged full cooperation with the DOJ and has committed to maintaining the integrity of its operations.

The Broader Implications for the Healthcare Industry

The expanded investigation into UnitedHealth has broader implications for the healthcare sector, particularly for pharmacy benefits managers (PBMs). PBMs like Optum Rx play a crucial role in negotiating drug prices and managing reimbursements, but their opaque business practices have long been criticized. The DOJ’s probe could serve as a wake-up call for the industry, potentially leading to stricter regulatory oversight and increased transparency.

For UnitedHealth, the stakes are especially high. As one of the largest healthcare providers in the U.S., the company’s practices set a benchmark for the industry. Any findings of misconduct could result in substantial fines, further regulatory scrutiny, and lasting damage to its reputation. Conversely, a clean bill of health from the DOJ could help the company rebuild investor confidence and stabilize its financial outlook.

The ongoing DOJ investigation into UnitedHealth Group represents a critical juncture for the company and the broader healthcare industry. While the full implications of the probe remain to be seen, its outcome will undoubtedly shape the future of healthcare regulation and corporate accountability.